Contrasting Cara Therapeutics (CARA) & Its Competitors
Cara Therapeutics (NASDAQ: CARA) is one of 197 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it contrast to its peers? We will compare Cara Therapeutics to related companies based on the strength of its valuation, earnings, profitability, dividends, institutional ownership, risk and analyst recommendations.
Risk & Volatility
Cara Therapeutics has a beta of 3.09, meaning that its share price is 209% more volatile than the S&P 500. Comparatively, Cara Therapeutics’ peers have a beta of 1.63, meaning that their average share price is 63% more volatile than the S&P 500.
This is a summary of recent recommendations for Cara Therapeutics and its peers, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Cara Therapeutics Competitors||475||2254||6144||119||2.66|
Cara Therapeutics presently has a consensus price target of $26.63, suggesting a potential upside of 113.34%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 1.48%. Given Cara Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Cara Therapeutics is more favorable than its peers.
Earnings & Valuation
This table compares Cara Therapeutics and its peers gross revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Cara Therapeutics||$911,000.00||-$64.69 million||-5.36|
|Cara Therapeutics Competitors||$207.75 million||-$2.17 million||0.61|
Cara Therapeutics’ peers have higher revenue and earnings than Cara Therapeutics. Cara Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
This table compares Cara Therapeutics and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Cara Therapeutics Competitors||-3,984.80%||-117.96%||-44.22%|
Insider and Institutional Ownership
61.1% of Cara Therapeutics shares are held by institutional investors. Comparatively, 48.6% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 7.5% of Cara Therapeutics shares are held by insiders. Comparatively, 14.0% of shares of all “Biotechnology & Medical Research” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Cara Therapeutics beats its peers on 7 of the 12 factors compared.
Cara Therapeutics Company Profile
Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. It is developing a class of product candidates that target the body’s peripheral nervous system. The Company operates through the activities related to the discovery and development of therapeutics to treat serious medical conditions, including pain and pruritus. Its product candidate pipeline includes I.V. CR845 for acute pain; I.V. CR845 for uremic pruritus; Oral CR845 for acute and chronic pain, and CR701 for neuropathic and inflammatory pain. I.V. CR845 is an injectable version of peripheral kappa opioid receptor agonist, which is intended for the treatment of acute pain in an acute care setting. CR845 has exhibited anti-pruritic, or anti-itch, potency in standard preclinical models.
Receive News & Ratings for Cara Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.